BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jordan CJ, Feng ZW, Galaj E, Bi GH, Xue Y, Liang Y, McGuire T, Xie XQ, Xi ZX. Xie2-64, a novel CB2 receptor inverse agonist, reduces cocaine abuse-related behaviors in rodents. Neuropharmacology 2020;176:108241. [PMID: 32712273 DOI: 10.1016/j.neuropharm.2020.108241] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Slosky LM, Pires A, Bai Y, Clark NB, Hauser ER, Gross JD, Porkka F, Zhou Y, Chen X, Pogorelov VM, Toth K, Wetsel WC, Barak LS, Caron MG. Establishment of multi-stage intravenous self-administration paradigms in mice. Sci Rep 2022;12:21422. [PMID: 36503898 DOI: 10.1038/s41598-022-24740-2] [Reference Citation Analysis]
2 Martinez Ramirez CE, Ruiz‐pérez G, Stollenwerk TM, Behlke C, Doherty A, Hillard CJ. Endocannabinoid signaling in the central nervous system. Glia 2022. [DOI: 10.1002/glia.24280] [Reference Citation Analysis]
3 Ferranti AS, Foster DJ. Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits. Front Neurosci 2022;16:925792. [DOI: 10.3389/fnins.2022.925792] [Reference Citation Analysis]
4 Galaj E, Hempel B, Moore A, Klein B, Bi GH, Gardner EL, Seltzman HH, Xi ZX. Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research. Transl Psychiatry 2022;12:286. [PMID: 35851573 DOI: 10.1038/s41398-022-02059-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 García-Gutiérrez MS, Navarrete F, Gasparyan A, Navarro D, Morcuende Á, Femenía T, Manzanares J. Role of Cannabinoid CB2 Receptor in Alcohol Use Disorders: From Animal to Human Studies. Int J Mol Sci 2022;23:5908. [PMID: 35682586 DOI: 10.3390/ijms23115908] [Reference Citation Analysis]
6 Yuan J, Jiang C, Wang J, Chen CJ, Hao Y, Zhao G, Feng Z, Xie XQ. In Silico Prediction and Validation of CB2 Allosteric Binding Sites to Aid the Design of Allosteric Modulators. Molecules 2022;27:453. [PMID: 35056767 DOI: 10.3390/molecules27020453] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 He XH, Galaj E, Bi GH, He Y, Hempel B, Wang YL, Gardner EL, Xi ZX. β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms. Front Pharmacol 2021;12:722476. [PMID: 34566647 DOI: 10.3389/fphar.2021.722476] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]